000076301 001__ 76301 000076301 005__ 20190115134122.0 000076301 037__ $$aTAZ-TFM-2018-248 000076301 041__ $$aeng 000076301 1001_ $$aReina Ortiz, Chantal 000076301 24200 $$aExpansion of NK cells for the treatment of multiple myeloma 000076301 24500 $$aExpansion of NK cells for the treatment of multiple myeloma 000076301 260__ $$aZaragoza$$bUniversidad de Zaragoza$$c2018 000076301 506__ $$aby-nc-sa$$bCreative Commons$$c3.0$$uhttp://creativecommons.org/licenses/by-nc-sa/3.0/ 000076301 520__ $$aThe purpose of this study was to test the efficacy of expanded natural killer cells (eNKs) as a treatment against multiple myeloma (MM) cell lines and MM patient bone marrow aspirates. The cytotoxic effect of eNKs was studied alone and in combination with daratumumab, anti-CD38 monoclonal antibody approved for use in multiple myeloma patients. In multiple myeloma cell lines, eNKs were found to have a dramatic cytotoxic effect against the cells. For the patient samples, when eNKs were harvested during the optimum expansion period, they produced a cytotoxic effect against the MM cells. Daratumumab was also effective against some of the patient samples. However, when combined, eNKs and daratumumab produced a greater percent of specific cell death than both separately, on all cells tested. Combination therapy maximizes the effect of each individual treatment. This important finding supports the possible use of combination eNKs with daratumumab therapy against multiple myeloma in further trials. 000076301 521__ $$aMáster en Biología Molecular y Celular 000076301 540__ $$aDerechos regulados por licencia Creative Commons 000076301 700__ $$aANEL BERNAL, ALBERTO$$edir. 000076301 7102_ $$aUniversidad de Zaragoza$$bBioquímica y Biología Molecular y Celular$$cBioquímica y Biología Molecular 000076301 8560_ $$f676744@celes.unizar.es 000076301 8564_ $$s4523491$$uhttps://zaguan.unizar.es/record/76301/files/TAZ-TFM-2018-248.pdf$$yMemoria (eng) 000076301 909CO $$ooai:zaguan.unizar.es:76301$$pdriver$$ptrabajos-fin-master 000076301 950__ $$a 000076301 951__ $$adeposita:2019-01-15 000076301 980__ $$aTAZ$$bTFM$$cCIEN 000076301 999__ $$a20180628125139.CREATION_DATE